Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC reduced its position in Replimune Group, Inc. (NASDAQ:REPL) by 41.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 34,547 shares of the company’s stock after selling 24,040 shares during the period. Los Angeles Capital Management LLC’s holdings in Replimune Group were worth $418,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Baker BROS. Advisors LP increased its holdings in shares of Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after acquiring an additional 1,000,000 shares during the last quarter. Braidwell LP boosted its holdings in Replimune Group by 203.0% in the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after purchasing an additional 2,057,460 shares during the period. State Street Corp increased its stake in Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after purchasing an additional 1,182,181 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Replimune Group by 17.9% during the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock worth $15,657,000 after purchasing an additional 217,308 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its position in shares of Replimune Group by 45.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock worth $8,371,000 after buying an additional 238,747 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Insider Activity at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now directly owns 202,014 shares in the company, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 8.80% of the stock is currently owned by insiders.

Replimune Group Stock Performance

Shares of REPL stock opened at $12.12 on Tuesday. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $17.00. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The firm has a market capitalization of $933.42 million, a price-to-earnings ratio of -3.95 and a beta of 1.30. The business has a 50 day simple moving average of $12.79 and a 200 day simple moving average of $12.02.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). On average, equities research analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current year.

Wall Street Analyst Weigh In

REPL has been the topic of several research reports. BMO Capital Markets increased their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Jefferies Financial Group upped their target price on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. HC Wainwright raised their price target on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Finally, JPMorgan Chase & Co. upped their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Replimune Group presently has an average rating of “Buy” and an average target price of $19.43.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.